Dr. Sharman briefly discusses the whys of the rather unique Watch and Wait 'treatment' decision for CLL, mentioning the relevance of clonal evolution, reports on the typical treatments provided to those with CLL in the United States and states that "Right now in 2013 we do not know what the best front line therapy actually is". He then shares his opinion on what is currently best for patients needing treatment.
This latest blog is, as usual, informative and easy to read - particularly if you anticipate needing your first treatment soon.
cll-nhl.com/2013/03/choosin...
Neil